Sykehusinnkjøp HF 916879067 Postboks 40 Vadsø 9811 Erik Lindseth erik.lindseth@sykehusinnkjop.no https://permalink.mercell.com/81379186.aspx http://www.sykehusinnkjop.no/ Voluntary ex ante transparency notice — Framework agreement for sterility testing | St.Olav, UNN, SAN 2017/1316 Olavs Hospital HF (organisation nº 883 974 832), Sykehusapotek Nord (organisation nº 983 974 937) and Universitetssykehuset Nord-Norge (organisation no. 983 974 899) intend to enter into a 4 year framework agreement with Curida AS for providing sterility testing services. After examined the market the Contracting Authorities were unable to find any other suitable service provider. The contracting authorities produce fluorodeoxyglucose (FDG) and other radiopharmaceuticals. The selected provider has an approved manufacturer permission from the Norwegian Medicines Agency. This is an absolute requirement for providing this service. In the middle of 2017 Sykehusinnkjøp HF published an equivalent Voluntary ex ante transparency notice without any obligations from the market. The deadline for appeals against signing of the contract is set at 9.3.2018 (9:00). 5000000.00 Sterility testing of radiopharmaceuticals. After examined the market the Contracting Authorities were unable to find any other suitable service provider. The Contracting Authorities produce fluorodeoxyglucose (FDG) and other radiopharmaceuticals. The selected provider has an approved manufacturer permission from the Norwegian Medicines Agency. This is an absolute requirement for providing this service. In the middle of 2017 Sykehusinnkjøp HF published an equivalent Voluntary ex ante transparency notice without any obligations from the market. 2017/1316 A framework agreement for sterility testing. 2018-02-23 Curida AS Elverum 5000000.00 Klagenemnda for offentlige anskaffelser Bergen 2018-02-26
See tender at TED: http://ted.europa.eu/udl?uri=TED:NOTICE:088777-2018:TEXT:EN:HTML